Drug Trial Radar · NCT07268638
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Dec 3, 2025
Primary completion
Jun 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- Akebia TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of praliciguat in adults with biopsy-confirmed focal segmental glomerulosclerosis (FSGS). Participants will be randomized 1:1 to receive praliciguat or placebo for initial 24 week treatment period. Following this double-blind period, all participants will receive praliciguat in an open-label period for an additional 24 weeks. Participants responding to treatment will be offered the opportunity to participate in the long-term safety extension study.
Conditions
- Focal Segmental Glomerulosclerosis
Interventions
Praliciguat (Part A)Drug
Oral Tablet
Placebo (Part A)Other
Oral Tablet
Praliciguat (Part B)Drug
Oral Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in urine protein-to-creatinine ratio (UPCR) (Part A)Time frame: Baseline (Day 1) and up to Week 24
- Proportion of participants with TEAEs, serious adverse events (SAEs), and treatment-emergent adverse events of special interest (AESIs). (Part A)Time frame: Time Frame: Up to Week 52
Locations
32 sites in 1 country. Site status is shown where the registry gives one.
Investigator Site #2
Chula Vista, California · Recruiting
Investigator Site #28
Garden Grove, California · Recruiting
Investigator Site #14
Los Angeles, California · Recruiting
Investigator Site #12
San Dimas, California · Recruiting
Investigator Site #13
Arvada, Colorado · Recruiting
Investigator Site #17
Boca Raton, Florida · Recruiting
Investigator Site #6
Coral Springs, Florida · Recruiting
Investigator Site #25
Hialeah, Florida · Recruiting
Investigator Site #7
Miami, Florida · Recruiting
Investigator Site #8
Orlando, Florida · Recruiting
Investigator Site #29
Augusta, Georgia · Recruiting
Investigator Site # 1
Lawrenceville, Georgia · Recruiting
Investigator Site #3
Chicago, Illinois · Terminated
Investigator Site #11
Louisville, Kentucky · Recruiting
Investigator Site #32
Catonsville, Maryland · Recruiting
Investigator Site #24
Worcester, Massachusetts · Recruiting
Investigator Site #15
Livonia, Michigan · Recruiting
Investigator Site #10
Pontiac, Michigan · Recruiting
Investigator Site #27
Valhalla, New York · Recruiting
Investigator Site #16
New Bern, North Carolina · Recruiting
Investigator Site #31
Shelby, North Carolina · Recruiting
Investigator Site #20
Cleveland, Ohio · Recruiting
Investigator Site #30
Bethlehem, Pennsylvania · Recruiting
Investigator Site #19
Bridgeville, Pennsylvania · Recruiting
Investigator Site #22
Butler, Pennsylvania · Recruiting
Investigator Site #23
Goose Creek, South Carolina · Recruiting
Investigator Site #4
Chattanooga, Tennessee · Recruiting
Investigator Site #5
Arlington, Texas · Recruiting
Investigator Site #21
Dallas, Texas · Recruiting
Investigator Site #9
Dallas, Texas · Recruiting
Investigator Site #18
Houston, Texas · Recruiting
Investigator Site #26
Roanoke, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.